Remarkably, IDH-C35, a mutant IDH1-specific inhibitor, in combination with a peptide-based vaccine immunotherapy significantly improves the survival of mice bearing GL261 R132H gliomas compared to vaccine alone, providing evidence that epigenetic agents may sensitize patients to concurrent or subsequent immune therapy. This evidence concerns the gene IDH2 and central nervous system cancer.